H.C. Wainwright launched coverage of IVERIC Bio (NASDAQ:ISEE) with a “buy” rating and price target of $20. The stock closed at $9.07 on Aug. 18. Analyst Matthew Caufield writes that IVERIC’s retinal platform...
Alliance Global Partners downgraded IMAC Holdings (NASDAQ:IMAC) to “neutral” and reduced its price target to $1.75 from $2.35 after the Center for Medicare and Medicaid Services (CMS) requested repayment of $2.9-million...
SVB Leerink initiated coverage of Amryt Pharma PLC (NASDAQ:AMYT) with an “outperform” rating and price target of $22. Analyst Mani Foroohar, M.D., writes that Amryt’s model of acquiring niche commercial or near...
Cantor Fitzgerald launched coverage of Portage Biotech (NASDAQ:PRTG) with an “overweight” rating and $35 price target. The stock closed at $18.95 on Aug. 18. Portage Biotech is a clinical biopharmaceutical company...
Cantor Fitzgerald upgraded MedMen Enterprises (OTCQB:MMNFF) to a “neutral” rating from “underweight” with a new price target of 30 cents after Tilray (NASDAQ:TLRY) purchased a 21% contingent stake in MedMen for $118...
Echelon Capital Markets raised its price target for Diagnos (TSXV:ADK) to $1.55 (Canadian) from 95 cents after it signed a memorandum of understanding (MoU) for a potential worldwide distribution agreement for its CARA...
Raymond James upgraded HLS Therapeutics (TSX:HLS) to “outperform” from “market perform” and raised its price target to $26 (Canadian) from $24 after Pfizer agreed to co-market HLS’s cardiovascular drug...
SVB Leerink raised its price target for Travere Therapeutics (NASDAQ:TVTX) to $37 from $27 and maintained an “outperform” rating after the company reported interim data from the Phase 3 PROTECT study with sparsentan in...
H.C. Wainwright downgraded Sesen Bio (NASDAQ:SESN) to “neutral” from “buy” and removed its price target after the company on Aug. 13 received a complete response letter from the FDA. The stock closed at $2.11 on Aug. 13...
SVB Leerink launched coverage of RAPT Therapeutics (NASDAQ:RAPT) with an “outperform” rating and a $49 price target. The stock closed at $33.07 on Aug. 11. RAPT is a clinical-stage biopharmaceutical company developing...